Immunglobulin Substitution Therapy in Hematological Patients with secondary Antibody Deficiency

被引：0
作者：
Braschler, Thomas R. [1 ]
Zeerleder, Sacha [1 ,2 ]
机构：
[1] Luzerner Kantonsspital, Abt Hamatol, Spitalstr, CH-6000 Luzern 16, Switzerland
[2] Univ Spital Bern, Inselspital, Univ Klin Hamatol & Hamatol Zentrallab, Bern, Switzerland
来源：
THERAPEUTISCHE UMSCHAU | 2022年 / 79卷 / 06期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; IMMUNOGLOBULIN; HYPOGAMMAGLOBULINEMIA; REPLACEMENT; RITUXIMAB; SAFETY;
D O I：
10.1024/0040-5930/a001364
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hematological malignancies and immunochemotherapy are frequently associated with secondary cellular and humoral immunodeficiencies. Due to the growing application of effective therapeutic antibodies, and cellular therapies specifically targeting and hence depleting antibody producing cells (B- and plasma cells) the incidence of secondary antibody deficiencies in the daily practice is increasing. This article will provide a short overview of the etiology of secondary antibody deficiencies in hematological patients. Then, it will discuss the efficacy and indication of immunoglobulin substitution therapy in these patients and finally address the choice of the respective preparation.
引用
收藏
页码：295 / 300
页数：6
相关论文
共 18 条
  • [1] Risk factors for hypogammaglobulinemia after allo-SCT
    Arai, Y.
    Yamashita, K.
    Mizugishi, K.
    Kondo, T.
    Kitano, T.
    Hishizawa, M.
    Kadowaki, N.
    Takaori-Kondo, A.
    [J]. BONE MARROW TRANSPLANTATION, 2014, 49 (06) : 859 - 861
  • [2] Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
    Barmettler, Sara
    Ong, Mei-Sing
    Farmer, Jocelyn R.
    Choi, Hyon
    Walter, Jolan
    [J]. JAMA NETWORK OPEN, 2018, 1 (07)
  • [3] BRUTON OC, 1952, PEDIATRICS, V9, P722
  • [4] BUNCH C, 1988, NEW ENGL J MED, V319, P902
  • [5] IMMUNOGLOBULIN REPLACEMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA - A COMPARISON OF 2 DOSE REGIMES
    CHAPEL, H
    DICATO, M
    GAMM, H
    BRENNAN, V
    RIES, F
    BUNCH, C
    LEE, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) : 209 - 212
  • [6] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Cohen, Stanley B.
    Emery, Paul
    Greenwald, Maria W.
    Dougados, Maxime
    Furie, Richard A.
    Genovese, Mark C.
    Keystone, Edward C.
    Loveless, James E.
    Burmester, Gerd-Ruediger
    Cravets, Matthew W.
    Hessey, Eva W.
    Shaw, Timothy
    Totoritis, Mark C.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2793 - 2806
  • [7] Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
    Cordeiro, Ana
    Bezerra, Evandro D.
    Hirayama, Alexandre V.
    Hill, Joshua A.
    Wu, Qian V.
    Voutsinas, Jenna
    Sorror, Mohamed L.
    Turtle, Cameron J.
    Maloney, David G.
    Bar, Merav
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : 26 - 33
  • [8] Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?
    Dhalla, Fatima
    Lucas, Mary
    Schuh, Anna
    Bhole, Malini
    Jain, Rashmi
    Patel, Smita Y.
    Misbah, Siraj
    Chapel, Helen
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 277 - 282
  • [9] Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
    Hill, Joshua A.
    Li, Daniel
    Hay, Kevin A.
    Green, Margaret L.
    Cherian, Sindhu
    Chen, Xueyan
    Riddell, Stanley R.
    Maloney, David G.
    Boeckh, Michael
    Turtle, Cameron J.
    [J]. BLOOD, 2018, 131 (01) : 121 - 130
  • [10] Johnsrud J.J., 2017, Open Forum Infectious Diseases, V4, pS702, DOI DOI 10.1093/OFID/OFX163.1884
12